Clinical Trial News and Research

RSS

New drug shows promising results with manageable side effects for treating melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.

3 Jun 2013

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

3 Jun 2013

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center led by Dr. Antoni Ribas, professor of medicine in the division of hematology-oncology, report preliminary results showing significant antitumor activity with very manageable side effects from a new drug being tested in patients with advanced melanoma, the deadliest form of skin cancer.

3 Jun 2013

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists.

3 Jun 2013

New clinical trial may help reduce radiation dose for patients with HPV-positive oropharyngeal cancer

Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.

1 Jun 2013

New therapy for lung cancer produces manageable side effects

A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.

1 Jun 2013

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacological therapy that shows promise for treating both solid-tumor cancers and hematologic malignancies.

1 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

Omeros announces positive results from OMS824 Phase 1 clinical program

Omeros Corporation today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program.

31 May 2013

Ragweed allergy sublingual immunotherapy: an interview with Dr. Peter Creticos, Johns Hopkins University School of Medicine

Ragweed is a dominant seasonal allergen in North America (~26% of US and North American population is allergic to this noxious weed which pollinates from early August to early October).

31 May 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

NYC public health officials launch new program to locate lost to follow-up patients with HIV

Public health officials in New York City have launched a successful program to locate HIV-positive patients who have been "lost to follow-up" and reconnect them with treatment services, reports a study published in AIDS, official journal of the International AIDS Society.

31 May 2013

Mayo Clinic introduces Individualized Medicine Clinic in Minnesota, Florida and Arizona

You have a serious medical condition, but the conventional tests fail to find an answer. You still have no diagnosis and no effective treatment. What do you do? Mayo Clinic has always been a destination for patients seeking answers. Now, Mayo is taking that concept to the next level with the public launch of its Individualized Medicine Clinic -- at all three of its campuses, in Minnesota, Florida and Arizona.

31 May 2013

Comprehensive analyses of the benefits and risks of NSAIDs

Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published in the current issue of The Lancet the most comprehensive analyses of the benefits and risks of non-steroidal anti-inflammatory drugs, which include cyclo-oxygenase-2 inhibitors (coxibs).

31 May 2013

Be ready for the next generation of cancer treatments

We cordially invite you to attend Markers in Cancer, a joint meeting by ASCO, EORTC & NCI which will be held 7 - 9 November 2013 in Brussels.

31 May 2013

PharmAthene announces lifting of clinical hold on proposed SparVax Phase II study

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Food and Drug Administration has lifted the clinical hold previously placed on a proposed Phase II study of SparVax, a next generation recombinant anthrax vaccine.

31 May 2013

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

30 May 2013

Isaiah J. Fidler earns 2013 American Cancer Society Medal of Honor for Basic Research

When Isaiah J. Fidler, D.V.M., Ph.D., left his veterinary surgical practice to pursue a doctorate that would allow him to study and combat the lethal spread of cancer to other organs, he got lots of advice. The common message: Don't go there.

30 May 2013

Doctors perform investigational procedure on six patients using ADRCs to treat heart failure

Doctors at the Texas Heart Institute at St. Luke's Episcopal Hospital announced that they have performed an investigational procedure on six patients in a new FDA-approved clinical trial to evaluate therapy that uses regenerative cells derived from a patient's own adipose (body fat) tissue to treat a severe form of heart failure.

30 May 2013

Clinical Trial News and Research

New drug shows promising results with manageable side effects for treating melanoma

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

New clinical trial may help reduce radiation dose for patients with HPV-positive oropharyngeal cancer

New therapy for lung cancer produces manageable side effects

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

GLYX-13 drug induces antidepressant results without street drug side effects

Omeros announces positive results from OMS824 Phase 1 clinical program

Ragweed allergy sublingual immunotherapy: an interview with Dr. Peter Creticos, Johns Hopkins University School of Medicine

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

NYC public health officials launch new program to locate lost to follow-up patients with HIV

Mayo Clinic introduces Individualized Medicine Clinic in Minnesota, Florida and Arizona

Comprehensive analyses of the benefits and risks of NSAIDs

Be ready for the next generation of cancer treatments

PharmAthene announces lifting of clinical hold on proposed SparVax Phase II study

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Isaiah J. Fidler earns 2013 American Cancer Society Medal of Honor for Basic Research

Doctors perform investigational procedure on six patients using ADRCs to treat heart failure

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery